Johns Hop­kins and lo­cal biotech team up for new man­u­fac­tur­ing site; New oral drug plat­form to help ac­cel­er­ate R&D time­line

Johns Hop­kins Uni­ver­si­ty and a Mary­land-based biotech will join forces to de­vel­op a cell and gene ther­a­py pro­cess­ing fa­cil­i­ty at the uni­ver­si­ty, set to open in 2023.

Or­ge­n­e­sis will join forces on the POCare Cen­ter, al­so known as the Mary­land Cen­ter for Cell Ther­a­py Man­u­fac­tur­ing, in part thanks to a $5 mil­lion grant from the state. The fa­cil­i­ty will be 7,000 square feet, and help clin­i­cians and re­searchers at Johns Hop­kins with a more stream­lined path from the lab to pa­tient tri­als. This al­lows for more in-house man­u­fac­tur­ing, and less out­sourc­ing to third par­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER